MY129773A - An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine - Google Patents

An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Info

Publication number
MY129773A
MY129773A MYPI98003899A MYPI9803899A MY129773A MY 129773 A MY129773 A MY 129773A MY PI98003899 A MYPI98003899 A MY PI98003899A MY PI9803899 A MYPI9803899 A MY PI9803899A MY 129773 A MY129773 A MY 129773A
Authority
MY
Malaysia
Prior art keywords
japanese encephalitis
vero cell
attenuated
vaccine
virus adapted
Prior art date
Application number
MYPI98003899A
Other languages
English (en)
Inventor
Hyun Su Kim
Bruce Innis
Josept R Putnak
Ashok K Srivastava
Leonard N Binn
Doria R Dubois
Wang Don Yoo
Soo Ok Kim
Sung Hee Lee
Sang Bum Moon
Sun Pyo Hong
Young Cheol Shin
Yong Ju Chung
Kenneth H Eckels
Original Assignee
Cj Corp
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Corp, Us Army filed Critical Cj Corp
Publication of MY129773A publication Critical patent/MY129773A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI98003899A 1997-08-28 1998-08-26 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine MY129773A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19970042002 1997-08-28
KR19970042001 1997-08-28

Publications (1)

Publication Number Publication Date
MY129773A true MY129773A (en) 2007-04-30

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98003899A MY129773A (en) 1997-08-28 1998-08-26 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Country Status (15)

Country Link
US (1) US6309650B1 (enExample)
EP (2) EP1604685B1 (enExample)
JP (1) JP4161017B2 (enExample)
KR (1) KR100314404B1 (enExample)
CN (1) CN1142271C (enExample)
AU (1) AU748730B2 (enExample)
CA (1) CA2301000C (enExample)
DE (2) DE122009000037I2 (enExample)
DK (2) DK1604685T3 (enExample)
ES (2) ES2382946T3 (enExample)
FR (1) FR09C0037I2 (enExample)
MY (1) MY129773A (enExample)
NL (1) NL300391I2 (enExample)
NZ (1) NZ503522A (enExample)
WO (1) WO1999011762A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
CN1160454C (zh) * 1998-10-05 2004-08-04 财团法人阪大微生物病研究会 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
ES2388909T3 (es) * 1999-04-22 2012-10-19 The United States Of America, As Represented Bythe Secretary Of Agriculture Vacuna contra el virus del síndrome respiratorio y reproductivo porcino basada en aislado JA-142 aislada
WO2001076624A1 (en) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese b encephalitis vaccine and process for producing the same
EP1416986A4 (en) * 2001-06-29 2005-12-14 Becton Dickinson Co INTRADERMIC DISTRIBUTION OF VACCINES AND GENE THERAPEUTIC AGENTS VIA MICROCANNULE
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1922308A (zh) * 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
MY173418A (en) * 2007-12-26 2020-01-23 Daiichi Sankyo Co Ltd Method of producing japanese encephalitis avccines stably storable over long time and use of the vaccine
CN102112153B (zh) * 2008-06-04 2014-04-16 一般财团法人化学及血清疗法研究所 灭活日本脑炎病毒颗粒作为佐剂的用途
WO2010013601A1 (ja) * 2008-07-30 2010-02-04 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
RU2706693C2 (ru) * 2013-09-14 2019-11-20 Бхарат Байотек Интернэшнл Лимитед Вирусная вакцина и способы ее производства
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
EP4253403A3 (en) 2015-12-23 2023-12-27 Valneva Austria GmbH Zika virus purification
US10881723B2 (en) 2016-01-15 2021-01-05 Km Biologics Co., Ltd. Vaccine containing immobilized virus particles
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
SG11202001161YA (en) 2017-09-21 2020-03-30 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
CA3081581A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
US20210277361A1 (en) * 2018-08-27 2021-09-09 Mican Technologies Inc. Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
EP4428231A4 (en) * 2022-04-20 2025-11-19 Korea Nat Institute Of Health GENOTYPE 5 OF HIGH-TIRES JAPANESE ENCEPHALITIS VIRUS AND ITS USE
EP4652265A1 (en) 2023-01-18 2025-11-26 Valneva Austria GmbH Process for virus production in a bioreactor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
KR19990023955A (ko) 1999-03-25
WO1999011762A1 (en) 1999-03-11
ES2382946T3 (es) 2012-06-14
DE69837211D1 (de) 2007-04-12
CA2301000C (en) 2003-07-08
AU748730B2 (en) 2002-06-13
JP4161017B2 (ja) 2008-10-08
CN1142271C (zh) 2004-03-17
EP1025209B1 (en) 2007-02-28
US6309650B1 (en) 2001-10-30
DK1604685T3 (da) 2012-06-18
NZ503522A (en) 2001-06-29
DE122009000037I1 (de) 2009-11-05
DE69837211T2 (de) 2007-12-06
FR09C0037I2 (fr) 2021-11-05
EP1604685B1 (en) 2012-02-22
AU9004798A (en) 1999-03-22
KR100314404B1 (ko) 2002-10-12
CA2301000A1 (en) 1999-03-11
FR09C0037I1 (enExample) 2009-09-25
ES2281929T3 (es) 2007-10-01
NL300391I1 (nl) 2009-08-03
DK1025209T3 (da) 2007-06-25
NL300391I2 (nl) 2009-11-02
EP1025209A1 (en) 2000-08-09
EP1604685A2 (en) 2005-12-14
CN1272879A (zh) 2000-11-08
DE122009000037I2 (de) 2011-06-16
JP2001514844A (ja) 2001-09-18
EP1604685A3 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
MY129773A (en) An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
TW354765B (en) Catheter hub to nose engagement
KR970702965A (ko) 연료압력 진공반응식 비귀환 연료시스템(non-return fuel system with fuel pressure vaccum response)
FI972443L (fi) Polypeptidi, jonka allergeenisuus on vähentynyt
FI971262A7 (fi) Tehostajat, kuten asetosyringoni
MX9700486A (es) Ligando para receptor de cinasa transmembranal de hepatoma.
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
EP0670175A4 (en) EXHAUST BOILER.
WO2001013320A3 (de) Magnetkarte
EP0643263A3 (en) Illuminating combustion system.
ZA997011B (en) Attenuated forms of bovine viral diarrhea virus.
SI0806408T1 (en) Anti-viral compounds
SI0806410T1 (en) Anti-viral compounds
FR2704931B1 (fr) Réservoir notamment bouteille de gaz.
EP0647991A3 (en) Locking element for printed circuit board.
MX9804043A (es) Composiciones parasiticidas a base de polisiloxanos ciclicos.
SI0806411T1 (en) Anti-viral compounds
EP0685684A3 (de) Atmosphärischer Gasbrenner.
GB9302176D0 (en) Cylinder leak indicator cap (c.l.i.c.)
EP0711340A4 (en) HIGH YIELDS OF INFLUENCE VIRUS
DE69019334D1 (de) GaAs-Passivierung mittels Wasserstoffplasma.
FI915959A7 (fi) Foerbraenningsmotormaskin, saerskilt dieselmotor.
FR2747342B1 (fr) Perfectionnements aux chemises de classement, notamment de documents
FI955902A0 (fi) Tietoliikennejärjestelmä sekä tietoliikennevaihde sekä menetelmä
DE69824881D1 (de) Kompakte replikons des epstein-barr-virus.